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LFD1PAD4-mIPS1 and TPA-BclAD1D3-LAMP1, when delivered by GeneGun, protected 90% of 26 the animals against a lethal challenge with 25LD 50 spores of the Ames strain of Bacillus anthracis. 27 Single applications of either antigen component showed significantly lower protection rates, 28 indicating the beneficial interaction between anti-spore and anti-toxin components for an acellular 29 vaccine formulation. 30 31
Introduction 32
Anthrax is caused by Bacillus anthracis, a Gram-positive, spore forming, rod-shaped bacterium [1] . 33 Spores gain access via cutaneous, oral or inhalational routes where they germinate and develop into 34 vegetative bacilli which then replicate and produce toxins which eventually kill the host [2] . The 35 pathogen expresses two major plasmid encoded virulence factors, a gamma-linked poly-D-glutamic 36 acid capsule (pX02 [3] ) and a tripartite toxin (pX01 [4] ) comprised of Protective Antigen (PA) 1 , 37
Lethal Factor (LF) 2 and Edema Factor (EF) 3 [5] [6] . 38 Current live attenuated veterinary anthrax vaccines are less than ideal. They can cause problems in 39 sensitive animals such as goats and llamas, protection is short term, variation in vaccine quality can 40 cause vaccine failure and most importantly the live nature of the vaccine prevents its efficacy if 41 delivered at the same time as antibiotics [7] [8] . These limitations have stimulated the development 42 of non-living, component vaccines capable of inducing a broad spectrum immune response which 43 targets both toxaemia and bacteraemia. 44 The strong correlation between toxin neutralising activity (tna) 4 of PA-specific antibodies and 45 protection [9] has prompted efforts to develop vaccines based solely on domains which stimulate 46 antibodies with tna [10] [11] [12] . One such study which employed a fusion protein comprised of 47 domain 4 of PA (receptor binding site) and domain 1 of LF (PA binding site) protected mice against 48 1 PA -Protective Antigen 2 LF -Lethal Factor 3 EF -Edema Factor 4 tna -toxin neutralising activity a subsequent lethal challenge with B. anthracis spores [13] . To further assess the immunogenic 49 value of this protein we administered it as a DNA-vaccine in two different vectors and compared its 50 activity to that seen against full length rPA83. 51
In addition to neutralising the action of toxins the spore can also be targeted to prevent the pathogen 52 from gaining a foothold in the infected individual [14] [15] . Vaccination experiments with live 53 nonvirulent or formaldehyde-inactivated spores have shown that spore specific immune responses 54 can enhance the level of protection when given in combination with PA [16] . 55 56 One such component is the Bacillus collagen like protein of anthracis (BclA) 5 which forms hair-57 like structures projecting from the spore surface and represents a major spore immunogen [17] [18] . 58
The removal of the collagen-like region (CLR 6 , domain 2) from BclA has no detrimental effect on 59 immunogenicity and results in a smaller peptide which is easier to incorporate into a 60 multicomponent vaccine [19] [20] . In this study we determined the immunogenicity of a CLR-61 deficient version of BclA called rBclAD1D3 when administered as a DNA-vaccine in two different 62
vectors. 63 64
For the DNA vaccine studies we employed two different plasmid backbones (pDNAVaccUltra and 65 NTC7382) which varied with regards to intracellular routing signals and immune stimulatory 66 elements [21] . To improve in vivo antigen presentation we utilised intracellular routing signals 67 which directed vaccine peptides to the MHC I and MHC II pathways. To target the MHC II 68 pathway [22] we employed tissue plasminogen activator (TPA) 7 which routes newly expressed 69 proteins to the secretion pathway [23] and lysosome-associated membrane protein (LAMP1) 8 which 70 directs proteins to the endosome [24] [25] . To enhance MHC I presentation we employed ubiquitin 71 5 BclA -Bacillus collagen like protein of anthracis 6 CLR -collagen-like region 7 TPA -tissue plasminogen activator 8 LAMP1 -lysosome-associated membrane protein which directs the associated protein to the proteasome [26] [27] . 72
73
To enhance the immunogenicity of the expressed proteins we investigated the utility of two 74 molecular adjuvants. Mouse interferon-ß promoter stimulator 1 (mIPS-1) 9 incorporated into the 75 backbone of the antigen encoding plasmid significantly induces type I interferon and interferon-76 stimulated genes in a TLR-independent matter [28] helper-cell epitope of the sperm whale myoglobin SFISEAIIHVLHSRHPG [33] [34] . 82
The overall aim of this study was to determine the ability of BclA to confer additional 83 protectiveness when given together with a toxin-specific vaccine. (Qiagen, Venlo, Netherland) and pQE-30 (Qiagen) encoding either rPA83, rBclA or rLF were grown 90 and purified as described previously [35] . Proteins used for ELISA received no further treatment 91 while proteins used for vaccination were tested for endotoxin using the Limulus Amoebocyte Lysate 92
Endochrome-K test kit (Charles River, Wilmington, MA) as described by the manufacturer. 93
Endotoxin removal was performed via EndoTrap blue endotoxin removal system (Hyglos, Bernried, 94 Germany). 95
Preparation of DNA-vaccines 97
Providing of vector-backbones (pDNAVaccUltra and NTC7382) including signal sequences, 98 cloning of respective gene sequences and purification of the constructs was undertaken by the 99 Nature Technology Corporation (Lincoln, NE). The sequence for murine CIITA (Mn01492) was 100 acquired from GeneCopoeia (Rockville, MD) and the sequence of mIPS-1 was used as given for 101 pUNO1-mIPS1 (Genebank: NM_144888.2). Antigens used comprised of rPA83 (2208 bp) [35] , 102 LFD1PAD4 (1300 bp) [13] and BclAD1D3 (480 bp) [20] . Vaccines were prepared and applied as 103 described previously [35] . 104 105
Administration of vaccines and challenge 106
Trials were performed using 8-12 weeks old female outbred NMRI mice (Charles River). 107
Immunisation groups comprised of 10 animals, while groups which only received an adjuvant 108 (lipopeptide or CIITA) contained 5 individuals. 109
Mice were immunised 3 times at intervals of 2 weeks. Challenge was performed 3 weeks after the 110 last immunisation and mice were monitored for survival for up to 4 weeks. Blood was taken prior to 111 immunisation, before challenge and after the end of the challenge. All data presented is referring to 112 sera taken before the challenge unless stated otherwise. Preparation, vaccination and challenge of 113 the mice was performed under anesthesia with Isofluran (Actavis, Weiterstadt, Germany) using a 114 shown), thus normalising its effect to allow for a better discrimination between different antigens 125 and applications. Mice that died during the challenge or were killed via CO 2 after the end of the 126 challenge were dissected to prepare liver and spleen which were then plated on blood agar to verify 127 the presence of the pathogen. 128 129
Serology 130
ELISA was performed as described previously [35] . Secondary antibodies comprised of horseradish 131 peroxidase conjugated polyclonal goat anti-mouse IgG (Sigma-Aldrich), IgG1 and IgG2a (Acris, 132
San Diego, CA). Endpoint titres were defined as the reciprocal of the highest serum dilution that 133 resulted in an absorbance greater than two standard deviations above the average of the negative 134 control serum sample (pooled naive sera of the according group) with a minimum OD 414nm value of 135 0.1. 136 Sera were analysed for neutralising antibody titres via in vitro toxin neutralising assay (TNA) as 137 published previously [35] . The neutralisation titre (NT) corresponds to the inverse serum dilution at 138 which the toxin neutralisation yielded 50% (NT 50 ). The NT 50 was estimated using the SigmaPlot 139 regression wizard (4-parameter sigmoid regression curve). Detailed Titres are only described for 140 sera taken before the challenge. 141 fig. 1 and 2 ). The measured antibody titres as well as the NT 50 -titres 154 ( fig. 3 ) for the groups receiving either rPA83 or rBclA alone were similar to or higher than those 155 seen in the group given both proteins suggesting no synergistic effects or shift in subclass 156
dominance. 157
Each antigen when given alone did not provide significant protection while the combination 158 achieved 70% protection (tab. 1; fig. 4A ) indicating that rBclA and rPA83 augment each others 159 ability to protect. These findings are similar to those reported in a previous study where A/J mice 160 were challenged with spores of the Sterne strain of B. anthracis [14] . The authors of this study 161 concluded that BclA enhanced protection by inducing the opsonization of spores and stimulating the 162 production of antibodies which also inhibited germination. In addition PA-specific antibodies have 163 been shown to promote spore opsonization and the inhibition of germination in a similar manner to 164
BclA [36] . Thus the protection seen in animals given rPA83 and rBclA may be the result of a 165 synergy in the anti-spore effect rather than a feature of anti-toxin properties. This would explain 166 why we saw no correlation between survival and antibody titres (r s ≤ ±0.53). This applied also to 167 the NT 50 -titres of animals immunised with rPA83 as they had generated high toxin neutralising 168 antibodies, a feature which has previously been shown to correlate with protection in other animal 169 models [9] In a previous study we reported that the fusion protein LFD1PAD4 was able to fully protect A/J 178 mice against i.p. challenge with ~ 10 5 spores of the Sterne vaccine strain [13] . To determine if a 179 similar level of protection could be achieved when the antigen was presented in the context of a 180 DNA vaccine we introduced the gene encoding the fusion protein into two different DNA vectors 181
and compared the resulting immune responses to those seen using a DNA vaccine expressing full 182 length rPA83. The latter had been shown to significantly protect A/J mice from a lethal challenge 183 with the attenuated STI-1 vaccine strain [35] but not outbred mice from challenge with spores of the 184 fully virulent Ames strain [40] . 185
The DNA-vaccines elicited significantly lower (1-2 log10) anti-PA-antibody and NT 50 -titres 186 ( fig. 1and 3) than the protein vaccines which contained rPA83 (tab 1). While the TPA-LFD1PAD4-187 mIPS1 and TPA-rPA83-LAMP1 constructs stimulated similar anti-rPA83-IgG and -IgG1 titres they 188 were significantly higher than those seen using TPA-LFD1PAD4-LAMP1 which failed to elicit anti-189 rPA83 titres in the majority of the animals and thus was not distinctive of the pre-immune sera. 190
Of the two DNA constructs which contained LF the TPA-LFD1PAD4-mIPS1 vector induced higher 191 anti-rLF-IgG and -IgG1 titres ( fig. 5 ) and for both constructs the LF specific antibody response 192 before the challenge exceeded that seen against PA as has been noted previously [13] . for either DNA vaccine suggesting that the various routing signals had no detectable influence. The 220 only discernable difference between both concerned the IgG2a titres, which were detectable in all 221 individuals immunised with TPA-BclAD1D3-LAMP1 but not when BclAD1D3-Ubiquitin was 222 applied. It is possible that by using a GeneGun to deliver each DNA vaccine any beneficial effect 223 provided by targeting routing was masked [41] [42] . Our previous study with full length BclA 224 applied via GeneGun in a vector containing a different secretion signal, depicted a similar antibody 225 spectrum with a distinctive IgG1 bias [40] . 226
Both of the vaccines tested in our study protected 50% of the animals when challenged with fully 227 virulent spores (fig. 1B) . Analysis of the blood of animals which have survived challenge gave the 228 indication of a possible sterile infection as inferred from lack of PA antibodies [43] . To determine if we could further increase the level of protective immunity we co-immunised mice 235 with TPA-LFD1PAD4-mIPS1 and TPA-BclAD1D3-LAMP1 and subjected them to a lethal spore 236 challenge. The TPA-BclAD1D3-LAMP vector was selected for these studies as it had previously 237 been reported that DNA-vectors containing ubiquitin reacted adversely in the presence of other 238 DNA vector signal sequences [45] . Following a lethal spore challenge (25LD 50 ) 90% of the animals 239 survived and there was an increase in time to death for the single animal that succumbed to 240 infection (tab 1). 241
This increased protection was mirrored by an increase in the magnitude of the anti-rPA83-IgG and -242
IgG1 titres ( fig. 1 ) in that they significantly exceeded those of the single vectors although they were 243 still significantly lower than those seen in animals who had received protein vaccines containing 244 rPA83. The enhanced antibody titres against rPA83 were not associated with a higher NT 50 -titre 245 suggesting that the immune response was directed against other epitopes, possibly targets that 246 promote opsonization or inhibit germination. While the boost in anti-rPA83 titres as a consequence 247 of co-administration of spore antigens has been seen previously, it was in animals who had been 248 immunised with a protein formulation [44] . Our corresponding protein combination did not mimic 249 this trend. 250
The anti-rLF-IgG titres observed following co-administration were on the whole similar to those 251 seen after immunisation with TPA-LFD1PAD4-mIPS-1 alone and showed less scattering. The NT 50 -252 titre correlated strongly with anti-rLF-IgG (r s = +0.85) and -IgG1 titres (r s = +0.918) and weakly 253 with anti-rPA83 IgG and -IgG1 titres (r s ≥ +0.61). This was also true when TPA-LFD1PAD4-mIPS1 254 was given alone although the correlations were much weaker, thus the tna was positively influenced 255 for both parts of the antigen alike when combined with BclA under the presence of both adjuvants 256 while the overall titres generated were diversified. 257
Surprisingly the anti-rBclA titre of the DNA-vaccine combination and to a lesser extend that of the 258 protein combination, was significantly lower than that seen for either single vaccine application 259 ( fig. 2) . While an antagonistic effect of BclA on PA titre has been observed in other studies and has 260 been ascribed in part to -antigenic competition‖ [14] [46] [44] a negative effect of PA on BclA titres, 261 as seen here, has not been reported. Apart from the possibility of DNA-vector interferences [45] and 262 the possible influence of the presence of the adjuvant mIPS-1 in addition to CIITA we have no 263 explanation for this phenomenon. 264
However, the overall individual titres measured for the DNA-combination showed less scattering 265 within the group compared to the titres seen in the groups given a single vector. Thus BclA and PA 266
given together might have a balancing effect leading to a more stable immune response which 267 might contribute to enhanced survival. 268
In conclusion a DNA vaccine comprising a combination of plasmids encoding spore and toxin 269 targets conferred significantly greater protection than that seen for the individual DNA plasmids 270 (P ≤ 0.042), the single protein components (P ≤ 0.00008) and the vectors tested in our previous 271 study [40] . Furthermore it was found to be as effective as a comparable protein combination 272 (P = 0.251). To our knowledge this is the first example of a vaccination strategy against Anthrax in 273 which the protective immunity achieved using a DNA based approach exceeded that seen with 274 protein equivalents [40] . 
